Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAAH | O00519 | 3/20 | 0.34 |
| ▸ | CA12 | O43570 | 1/20 | 0.34 |
| ▸ | MMP2 | P08253 | 1/20 | 0.34 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | PKM | P14618 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | TYMS | P04818 | 1/20 | 0.32 |
| ▸ | PLA2G4A | P47712 | 2/20 | 0.31 |
| ▸ | ENO1 | P06733 | 1/20 | 0.31 |
| ▸ | CA2 | P00918 | 1/20 | 0.31 |
| ▸ | CA4 | P22748 | 1/20 | 0.31 |
| ▸ | LPAR3 | Q9UBY5 | 3/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18825589 | 0.82 | CAMK2A (0.36) | FAAHCA12MMP2CA14MEN1 | |
| SCHEMBL18848787 | 0.80 | MEN1 (0.50) | FAAHMMP2MEN1MAPK1KMT2A | |
| SCHEMBL4633674 | 0.80 | LMNA (0.41) | CA12MMP2CA14KMT2AALDH1A1 | |
| SCHEMBL10718498 | 0.79 | CA12 (0.38) | CA12MMP2CA14ALDH1A1ENO1 | |
| SCHEMBL18825598 | 0.78 | GAA (0.41) | FAAHMEN1MAPK1KMT2APLA2G4A | |
| SCHEMBL24637862 | 0.75 | GAA (0.42) | FAAHCA12MEN1MAPK1KMT2A | |
| SCHEMBL4635288 | 0.75 | ALDH1A1 (0.37) | CA12MMP2CA14ALDH1A1ENO1 | |
| SCHEMBL18825526 | 0.73 | PLA2G2C (0.30) | CA12MMP2CA14 | |
| SCHEMBL6173759 | 0.72 | FAAH (0.61) | FAAHMEN1MAPK1KMT2AALDH1A1 | |
| SCHEMBL11656666 | 0.70 | CYP2C9 (0.46) | CA12MMP2CA14MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11497813-B2 | Bortezomib conjugates and methods using same | BIOVINC, LLC (US) | 2022-11-15 | — | — | US | disclosed |
| EP-3371203-B1 | BORTEZOMIB CONJUGATES AND METHODS USING SAME | UNIV ROCHESTER (US) | 2020-02-26 | — | — | EP | disclosed |
| US-20180318425-A1 | Bortezomib Conjugates and Methods Using Same | BIOVINC, LLC | 2018-11-08 | — | — | US | disclosed |
| EP-3371203-A1 | BORTEZOMIB CONJUGATES AND METHODS USING SAME | University Of Rochester (US) | 2018-09-12 | — | — | EP | disclosed |
| WO-2017079262-A1 | BORTEZOMIB CONJUGATES AND METHODS USING SAME | UNIVERSITY OF ROCHESTER (US) | 2017-05-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11497813-B2 | Bortezomib conjugates and methods using same | BCR, PSMA6, PSMA5 | FAAH 4464/4885CA12 240/4885MMP2 1853/4885 |
| US-20180318425-A1 | Bortezomib Conjugates and Methods Using Same | BCR, PSMA6, PSMA5 | FAAH 4464/4885CA12 240/4885MMP2 1853/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.